Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE)

IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Profitability

This table compares IGM Biosciences and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IGM Biosciences	-7,534.03%	-155.42%	-61.04%
Gyre Therapeutics	-84.57%	-118.43%	-71.97%

Risk & Volatility

IGM Biosciences has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IGM Biosciences and Gyre Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IGM Biosciences	1	9	0	0	1.90
Gyre Therapeutics	0	0	0	0	0.00

IGM Biosciences presently has a consensus price target of $5.50, suggesting a potential upside of 313.53%. Given IGM Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Gyre Therapeutics.

Insider and Institutional Ownership

42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares IGM Biosciences and Gyre Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IGM Biosciences	$2.92 million	27.10	-$246.42 million	($3.64)	-0.37
Gyre Therapeutics	$105.03 million	9.71	-$92.93 million	N/A	N/A

Gyre Therapeutics has higher revenue and earnings than IGM Biosciences.

Summary

IGM Biosciences beats Gyre Therapeutics on 6 of the 11 factors compared between the two stocks.

About IGM Biosciences

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.